Literature DB >> 6753891

Captopril and atenolol combined with hydrochlorothiazide in essential hypertension.

L Andrén, B Karlberg, P Ohman, A Svensson, J Asplund, L Hansson.   

Abstract

1 Fifty-seven patients with mild or moderate essential hypertension, mean age 50 (range 31-69) were randomised to treatment with either captopril or atenolol. Twenty-six patients in each group completed the study. 2 Captopril (25-50 mg three times daily) and atenolol (50-100 mg once daily) caused a highly significant fall in blood pressure both supine and standing. 3 When hydrochlorothiazide (25-50 mg once daily) was added a further fall in blood pressure was observed in both groups. 4 Captopril as single drug caused no significant change in heart rate, while atenolol significantly reduced heart rate both supine and standing. 5 Two patients were excluded from the captopril group, one because of a reversible loss of taste and the other because of dizziness. Three patients were excluded from the atenolol group, two because of bradyarrhythmias and one because of inadequate blood pressure response. 6 Both captopril and atenolol were found to be effective antihypertensive agents, suitable for the treatment of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6753891      PMCID: PMC1427519          DOI: 10.1111/j.1365-2125.1982.tb02066.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme.

Authors:  E D Vaughan; R M Carey; C R Ayers; M J Peach
Journal:  J Clin Endocrinol Metab       Date:  1979-05       Impact factor: 5.958

2.  Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.

Authors:  D B Case; S A Atlas; J H Laragh; J E Sealey; P A Sullivan; D N McKinstry
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

Review 3.  The renin system in high blood pressure, from disbelief to reality: converting-enzyme blockade for analysis and treatment.

Authors:  J H Laragh
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

Review 4.  Captopril in the treatment of clinical hypertension and cardiac failure.

Authors:  A B Atkinson; J I Robertson
Journal:  Lancet       Date:  1979-10-20       Impact factor: 79.321

5.  Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.

Authors:  S A Atlas; D B Case; J E Sealey; J H Laragh; D N McKinstry
Journal:  Hypertension       Date:  1979 May-Jun       Impact factor: 10.190

6.  The Fifth Volhard Lecture. Specific inhibitors of renin.

Authors:  E Haber
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

7.  Converting enzyme inhibition with an orally active compound in hypertensive man.

Authors:  E L Bravo; R C Tarazi
Journal:  Hypertension       Date:  1979 Jan-Feb       Impact factor: 10.190

8.  Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension.

Authors:  C I Johnston; J A Millar; B P McGrath; P G Matthews
Journal:  Lancet       Date:  1979-09-08       Impact factor: 79.321

9.  Brain angiotensin II stimulates release of pituitary hormones, plasma catecholamines and increases blood pressure in dogs.

Authors:  B A Schölkens; W Jung; W Rascher; A Schömig; D Ganten
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

10.  Haemodynamic effects of captopril in hypertensive patients: comparison with saralasin.

Authors:  R Fagard; A Amery; P Lijnen; T Reybrouck
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

View more
  5 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

2.  Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients.

Authors:  J F Giudicelli; C Richer; A Mattei
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

3.  Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension.

Authors:  D Steru; M Childs; S Lancrenon; J M Languillat; A Mattei; B Millet; A Schwebig; A Stephan
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

4.  Captopril for refractory hypertension in patients with impaired renal function.

Authors:  M S Laher; P O'Regan; J F O'Donohoe; T B Counihan
Journal:  J R Soc Med       Date:  1985-05       Impact factor: 5.344

Review 5.  Choosing the right ACE inhibitor. A guide to selection.

Authors:  G Leonetti; C Cuspidi
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.